Key result
Catheter ablation cuts all-cause mortality ~42% vs medical therapy in heart failure with AF.
Why the study?
Whether catheter ablation improves outcomes in patients with heart failure and atrial fibrillation receiving guideline-recommended pharmacological therapy is controversial.
Does catheter ablation reduce all-cause mortality in patients with heart failure and atrial fibrillation?
Meta-Analysis (n=2,490)
Does catheter ablation reduce all-cause mortality in patients with heart failure and atrial fibrillation?
Catheter ablation improves survival, cardiac function, and quality of life in selected patients with heart failure and atrial fibrillation compared to medical therapy alone.
Answers are grounded in this paper and cite their sources.
Supports catheter ablation to reduce mortality in heart failure with atrial fibrillation; confirms benefit across 13 randomized trials.
Introduction Many patients with heart failure (HF) have or develop atrial fibrillation (AF), which may contribute to worsening symptoms, hospitalisations and mortality. Whether catheter ablation improves outcomes in patients with HF and AF receiving guideline-recommended pharmacological therapy (GRPT) is controversial. Aims A systematic review and meta-analysis of relevant randomised controlled trials (RCT)s on the role of catheter ablation in patients with AF and HF. Methods Public databases for trials published prior to 17th March 2025 and investigating the effects of catheter ablation on morbidity and mortality in patients with HF and AF were searched. Outcomes of interest were all-cause and cardiovascular mortality, adverse events due to HF or AF, changes in left ventricular ejection fraction (LVEF), 6-Minute Walking Distance (6-MWD) and Minnesota Living With Heart Failure Questionnaire (MLWHFQ) scores. Results Altogether, thirteen RCTs including 2,490 patients (predominantly aged <65 years; of whom 73% were men and 79% reported persistent AF) were identified. Blinding of intervention was not attempted. Only three RCTs assessed the effect of catheter ablation in patients with preserved LVEF. Overall, compared to GRPT alone, catheter ablation was associated with lower all-cause mortality (hazard ratio [HR]: 0.58; 95% confidence interval [CI]: 0.44-0.76), cardiovascular death (HR: 0.52; 95% CI: 0.36-0.74) and adverse events related to HF or AF (HR: 0.69; 95% CI: 0.53-089). In addition, catheter ablation improved LVEF (+6% mean difference (MD)[95% CI: +4% to +9%]) and MLWHFQ (-12 points MD [95% CI: -18 points to -6 points]), with a trend to enhanced 6-MWD (+18 meters MD [95% CI: -1 meter to +38 meters]). Conclusions For a selected group of patients with chronic HF and AF enrolled in un-blinded RCTs, catheter ablation improved cardiac function, wellbeing and outcomes, including all-cause mortality. Further RCTs are required to determine whether the benefits of catheter ablation extend to a broader population of patients at higher risk of procedural failure and recurrent AF.
No takes yet. Share an insight, caveat, or question.
Iaconelli et al. (2026) conducted a meta-analysis in Heart failure and atrial fibrillation (n=2,490). Catheter ablation vs. Guideline-recommended pharmacological therapy (GRPT) was evaluated on All-cause mortality (HR 0.58, 95% CI 0.44-0.76). Catheter ablation reduced all-cause mortality by 42% compared to guideline-recommended pharmacological therapy in patients with heart failure and atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: